Inferior Vena Cava Agenesis and Deep Vein Thrombosis: A Pharmacological Alternative to Vitamin K Antagonists
  • Inês Esteves Cruz
    Hospital Egas Moniz, Lisbon, Portugal
  • Pedro Ferreira
    Hospital Santa Maria, Lisbon, Portugal
  • Raquel Silva
    Hospital Egas Moniz, Lisbon, Portugal
  • Francisco Silva
    Hospital Egas Moniz, Lisbon, Portugal
  • Isabel Madruga
    Hospital Egas Moniz, Lisbon, Portugal

Keywords

Inferior vena cava agenesis, deep vein thrombosis, direct factor Xa inhibitors, rivaroxaban

Abstract

Inferior vena cava (IVC) agenesis is a rare congenital abnormality affecting the infrarenal segment, the suprarenal or the whole of the IVC. It has an estimated prevalence of up to 1% in the general population that can rise to 8.7% when abnormalities of the left renal vein are considered. Most IVC malformations are asymptomatic but may be associated with nonspecific symptoms or present as deep vein thrombosis (DVT). Up to 5% of young individuals under 30 years of age with unprovoked DVT are found to have this condition. Regarding the treatment of IVC agenesis-associated DVT, there are no standard guidelines. Treatment is directed towards preventing thrombosis or its recurrence. Low molecular weight heparin and oral anticoagulation medication, in particular vitamin K antagonists (VKAs) are the mainstay of therapy. Given the high risk of DVT recurrence in these patients, oral anticoagulation therapy is suggested to be pursued indefinitely. As far as we know, this is the first case reporting the use of a direct factor Xa inhibitor in IVC agenesis-associated DVT. Given VKA monitoring limitations, the use of a direct Xa inhibitor could be an alternative in young individuals with anatomical defects without thrombophilia, but further studies will be needed to confirm its efficacy and safety.

VIEW THE ENTIRE ARTICLE

References

  • Gensas C, Pires L, Kruse M, Leiria T, Gomes D, Lima G. Agenesis of the inferior vena cava. Rev Bras Cardiol Invasiva 2012;20(4):427–430.

  • Lambert M, Marboeuf P, Midulla M, Trillot N, Beregi JP, Mounier-Vehier C. Inferior vena cava agenesis and deep vein thrombosis: 10 patients and review of the literature. Vasc Med 2010;15:451–459.

  • Singh S, Bhatt T. Inferior vena cava agenesis: a rare cause of pelvic congestion syndrome. J Clin Diagn Res 2017;11(3):06–08.

  • Kalogridaki E, Kanioura E, Mavrigiannaki E, Katralis P, Filippou D, Skandalakis P, et al. Deep vein thrombosis and inferior vena cava agenesis. J Pediatr Surg Case Rep 2018;34:1–3.

  • Weitz JI, Lensing AWA, Prins MH, Bauersachs R, Beyer-Westendorf J, Bounameaux H, et al. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med 2017;376:1211–1222.

  • Broholm R, Jorgensen M, Just S, Jensen LP, Baekgaard N. Acute iliofemoral venous thrombosis in patients with atresia of the inferior vena cava can be treated successfully with catheter directed thrombolysis. J Vasc Interv Radiol 2011;22(6):801–805.

    • Views: 920
    HTML downloads: 478
    PDF downloads: 374

    Published: 2019-12-06
    Issue: Vol 6 No 12 (view)

    How to cite:
    1.
    Cruz IE, Ferreira P, Silva R, Silva F, Madruga I. Inferior Vena Cava Agenesis and Deep Vein Thrombosis: A Pharmacological Alternative to Vitamin K Antagonists. EJCRIM 2019;6 doi:10.12890/2019_001310.